HRP20231076T1 - Postupci detektiranja neutralizirajućih protutijela protiv leptina - Google Patents
Postupci detektiranja neutralizirajućih protutijela protiv leptina Download PDFInfo
- Publication number
- HRP20231076T1 HRP20231076T1 HRP20231076TT HRP20231076T HRP20231076T1 HR P20231076 T1 HRP20231076 T1 HR P20231076T1 HR P20231076T T HRP20231076T T HR P20231076TT HR P20231076 T HRP20231076 T HR P20231076T HR P20231076 T1 HRP20231076 T1 HR P20231076T1
- Authority
- HR
- Croatia
- Prior art keywords
- leptin
- labeled
- signal
- sample
- coated matrix
- Prior art date
Links
- 229940039781 leptin Drugs 0.000 title claims 33
- 238000000034 method Methods 0.000 title claims 13
- 230000003472 neutralizing effect Effects 0.000 title claims 7
- 102000016267 Leptin Human genes 0.000 claims 29
- 108010092277 Leptin Proteins 0.000 claims 29
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 29
- 239000011159 matrix material Substances 0.000 claims 11
- 239000000758 substrate Substances 0.000 claims 11
- 102000005861 leptin receptors Human genes 0.000 claims 6
- 108010019813 leptin receptors Proteins 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 5
- 210000002381 plasma Anatomy 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 230000000415 inactivating effect Effects 0.000 claims 4
- 239000003550 marker Substances 0.000 claims 3
- 238000005406 washing Methods 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 claims 2
- 239000013642 negative control Substances 0.000 claims 2
- 239000013641 positive control Substances 0.000 claims 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 108700008455 metreleptin Proteins 0.000 claims 1
- 229960000668 metreleptin Drugs 0.000 claims 1
- 229910052707 ruthenium Inorganic materials 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393632P | 2016-09-12 | 2016-09-12 | |
| PCT/US2017/051232 WO2018049424A1 (en) | 2016-09-12 | 2017-09-12 | Methods of detecting anti-leptin neutralizing antibodies |
| EP17849795.4A EP3509624B1 (en) | 2016-09-12 | 2017-09-12 | Methods of detecting anti-leptin neutralizing antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231076T1 true HRP20231076T1 (hr) | 2023-12-22 |
Family
ID=61559769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231076TT HRP20231076T1 (hr) | 2016-09-12 | 2017-09-12 | Postupci detektiranja neutralizirajućih protutijela protiv leptina |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10775386B2 (pl) |
| EP (2) | EP4283304A3 (pl) |
| JP (2) | JP7139317B2 (pl) |
| CN (1) | CN110139663B (pl) |
| BR (1) | BR112019004715A2 (pl) |
| CA (1) | CA3036551A1 (pl) |
| DK (1) | DK3509624T3 (pl) |
| EA (1) | EA201990720A1 (pl) |
| ES (1) | ES2959990T3 (pl) |
| FI (1) | FI3509624T3 (pl) |
| HR (1) | HRP20231076T1 (pl) |
| HU (1) | HUE063647T2 (pl) |
| MX (1) | MX2019002818A (pl) |
| PL (1) | PL3509624T3 (pl) |
| PT (1) | PT3509624T (pl) |
| RS (1) | RS64850B1 (pl) |
| SI (1) | SI3509624T1 (pl) |
| WO (1) | WO2018049424A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019004715A2 (pt) | 2016-09-12 | 2019-07-16 | Aegerion Pharmaceuticals Inc | métodos para detectar anticorpos neutralizantes anti-leptina |
| WO2019241653A1 (en) * | 2018-06-16 | 2019-12-19 | Board Of Regents, The University Of Texas System | Weight loss regimen |
| KR20210041009A (ko) * | 2018-08-03 | 2021-04-14 | 브리스톨-마이어스 스큅 컴퍼니 | 항-약물 항체를 검출하는 방법 |
| CN111983226A (zh) * | 2020-03-25 | 2020-11-24 | 新加坡国立大学 | SARSr-CoV抗体的检测 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
| US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
| US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
| US5580954A (en) | 1995-01-31 | 1996-12-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| WO1996023515A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5594101A (en) | 1995-03-03 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| WO1996040912A1 (en) | 1995-06-07 | 1996-12-19 | Amgen Inc. | Ob protein compositions and method |
| PL324284A1 (en) | 1995-06-30 | 1998-05-11 | Lilly Co Eli | Methods of treating diabetes |
| JP4173913B2 (ja) | 1995-08-17 | 2008-10-29 | アムジエン・インコーポレーテツド | Ｏｂタンパク質組成物を用いて血中脂質レベルを減少させ又は減少した血中脂質レベルを維持する方法 |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| EP1285664B1 (en) | 1995-11-22 | 2010-01-20 | Amgen Inc. | Methods of increasing lean tissue mass using OB protein compositions |
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| AU2670897A (en) | 1996-04-04 | 1997-10-29 | Amgen, Inc. | Fibulin pharmaceutical compositions and related methods |
| WO1998006752A1 (en) | 1996-08-16 | 1998-02-19 | The Rockefeller University | A leptin binding protein and its use in methods for diagnosing and treating abnormalities of the endogenous leptin pathway |
| JP2001501177A (ja) | 1996-08-30 | 2001-01-30 | アムジエン・インコーポレーテツド | Ｏｂタンパク質受容体をアップレギュレートすることによりｏｂタンパク質に対する個体の感受性を増加させる方法 |
| WO1998012224A1 (en) | 1996-09-20 | 1998-03-26 | Hoechst Aktiengesellschaft | Use of leptin antagonists for treating insulin resistance in type ii diabetes |
| EA004790B1 (ru) | 1996-12-20 | 2004-08-26 | Амген Инк. | Композиции на основе слитого белка ов и способы их применения |
| CA2286098C (en) | 1997-04-17 | 2009-07-07 | Amgen Inc. | Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods |
| AU2951797A (en) | 1997-06-06 | 1998-12-21 | Smithkline Beecham Plc | Use of leptin antagonists for the treatment of diabetes |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| DE69921486T2 (de) | 1998-08-10 | 2006-02-02 | Amgen Inc., Thousand Oaks | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren |
| EP1118001A1 (en) | 1998-10-02 | 2001-07-25 | Amgen Inc. | Method to determine a predisposition to leptin treatment |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| ATE323766T1 (de) | 1999-02-12 | 2006-05-15 | Amgen Inc | Glykosylierte leptinzusammensetzungen und zugehörige verfahren |
| PL214862B1 (pl) | 2001-10-22 | 2013-09-30 | Amgen | Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny |
| AU2003290563A1 (en) | 2002-10-31 | 2004-05-25 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
| WO2004078944A2 (en) * | 2003-03-05 | 2004-09-16 | Maine Medical Center Research Institute | Thrombin, soluble jaggedi, and trap and growth of stem cells |
| US7754497B2 (en) * | 2003-08-29 | 2010-07-13 | Reverse Proteomics Research Institute Co., Ltd. | Method for immobilizing proteins |
| DE10353593A1 (de) | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| US7320868B2 (en) * | 2004-03-19 | 2008-01-22 | Arieh Gertler | Leptin binding domain compositions and methods thereto |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| EA201070609A1 (ru) | 2007-11-14 | 2010-12-30 | Амилин Фармасьютикалз, Инк. | Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств |
| GB201004058D0 (en) * | 2010-03-11 | 2010-04-28 | Consiglio Nazionale Ricerche | Diagnostic assay for obesity and related disorders |
| DK3241558T3 (da) | 2010-09-28 | 2021-04-26 | Aegerion Pharmaceuticals Inc | Højopløselige leptiner |
| US20130266963A1 (en) * | 2011-07-06 | 2013-10-10 | Nestec S.A. | Assay for detecting neutralizing autoantibodies to biologic therapy |
| JP6040464B2 (ja) | 2011-07-08 | 2016-12-07 | アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| MX2016005686A (es) | 2013-10-31 | 2016-08-11 | Regeneron Pharma | Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes. |
| RU2737719C2 (ru) * | 2015-02-27 | 2020-12-02 | Ионис Фармасьютикалз, Инк. | Модулирование экспрессии аполипопротеина с-iii (аросiii) у пациентов с липодистрофией |
| BR112019004715A2 (pt) | 2016-09-12 | 2019-07-16 | Aegerion Pharmaceuticals Inc | métodos para detectar anticorpos neutralizantes anti-leptina |
-
2017
- 2017-09-12 BR BR112019004715A patent/BR112019004715A2/pt unknown
- 2017-09-12 WO PCT/US2017/051232 patent/WO2018049424A1/en active Application Filing
- 2017-09-12 EA EA201990720A patent/EA201990720A1/ru unknown
- 2017-09-12 DK DK17849795.4T patent/DK3509624T3/da active
- 2017-09-12 PT PT178497954T patent/PT3509624T/pt unknown
- 2017-09-12 SI SI201731435T patent/SI3509624T1/sl unknown
- 2017-09-12 FI FIEP17849795.4T patent/FI3509624T3/fi active
- 2017-09-12 MX MX2019002818A patent/MX2019002818A/es unknown
- 2017-09-12 RS RS20231049A patent/RS64850B1/sr unknown
- 2017-09-12 EP EP23188153.3A patent/EP4283304A3/en active Pending
- 2017-09-12 EP EP17849795.4A patent/EP3509624B1/en active Active
- 2017-09-12 CA CA3036551A patent/CA3036551A1/en active Pending
- 2017-09-12 HR HRP20231076TT patent/HRP20231076T1/hr unknown
- 2017-09-12 PL PL17849795.4T patent/PL3509624T3/pl unknown
- 2017-09-12 US US15/702,719 patent/US10775386B2/en active Active
- 2017-09-12 CN CN201780069880.XA patent/CN110139663B/zh active Active
- 2017-09-12 ES ES17849795T patent/ES2959990T3/es active Active
- 2017-09-12 JP JP2019513974A patent/JP7139317B2/ja active Active
- 2017-09-12 HU HUE17849795A patent/HUE063647T2/hu unknown
-
2020
- 2020-08-18 US US16/996,281 patent/US11709166B2/en active Active
-
2022
- 2022-09-07 JP JP2022142227A patent/JP7509834B2/ja active Active
-
2023
- 2023-06-07 US US18/330,550 patent/US20230314447A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK3509624T3 (da) | 2023-11-13 |
| CA3036551A1 (en) | 2018-03-15 |
| HUE063647T2 (hu) | 2024-01-28 |
| EP3509624B1 (en) | 2023-08-09 |
| US20180074073A1 (en) | 2018-03-15 |
| US11709166B2 (en) | 2023-07-25 |
| US20230314447A1 (en) | 2023-10-05 |
| EP4283304A2 (en) | 2023-11-29 |
| US10775386B2 (en) | 2020-09-15 |
| JP2022176209A (ja) | 2022-11-25 |
| JP7509834B2 (ja) | 2024-07-02 |
| BR112019004715A2 (pt) | 2019-07-16 |
| JP2019529904A (ja) | 2019-10-17 |
| PT3509624T (pt) | 2023-08-28 |
| ES2959990T3 (es) | 2024-02-29 |
| RS64850B1 (sr) | 2023-12-29 |
| CN110139663B (zh) | 2024-05-07 |
| MX2019002818A (es) | 2019-08-29 |
| PL3509624T3 (pl) | 2024-03-25 |
| WO2018049424A1 (en) | 2018-03-15 |
| EP3509624A1 (en) | 2019-07-17 |
| CN110139663A (zh) | 2019-08-16 |
| EA201990720A1 (ru) | 2019-08-30 |
| JP7139317B2 (ja) | 2022-09-20 |
| SI3509624T1 (sl) | 2023-12-29 |
| EP4283304A3 (en) | 2024-02-28 |
| EP3509624A4 (en) | 2020-02-19 |
| FI3509624T3 (fi) | 2023-10-18 |
| US20200378988A1 (en) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231076T1 (hr) | Postupci detektiranja neutralizirajućih protutijela protiv leptina | |
| Choi et al. | Development of SPR biosensor for the detection of human hepatitis B virus using plasma-treated parylene-N film | |
| JP2019535015A5 (pl) | ||
| Jeon et al. | An electroactive biotin‐doped polypyrrole substrate that immobilizes and releases EpCAM‐positive cancer cells | |
| JP2019530875A5 (pl) | ||
| JP2009521215A5 (pl) | ||
| Riedel et al. | Diagnosis of Epstein–Barr virus infection in clinical serum samples by an SPR biosensor assay | |
| JP2020537128A5 (pl) | ||
| HRP20170427T1 (hr) | Testovi na adrenomedulin i postupci određivanja zrelog adrenomedulina | |
| WO2013132347A3 (en) | Improved elisa immunoassay for calprotectin | |
| HRP20171310T1 (hr) | Postupci procjenjivanja imunosnog odgovora na terapijsko sredstvo | |
| JP2014517311A5 (pl) | ||
| CN105393119A (zh) | 用于免疫试验的多重封闭物珠 | |
| WO2006126008A3 (en) | Improved immunoassay methods | |
| JP2014055944A5 (pl) | ||
| NZ607703A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| SE0201468D0 (sv) | Metod att använda luminescenta polymerer för detektion av biospecifik växelverkan | |
| EA200971114A1 (ru) | Определение антигенов, расположенных на эритроцитах, и антиэритроцитарных антител | |
| JP2012509477A5 (pl) | ||
| SI2638176T1 (en) | Enrichment and determination of fetal cells in the mother's blood and ligands for such use | |
| RU2014133701A (ru) | Способ детекции партнера по связыванию мультиспецифического связывающего агента | |
| Gao et al. | A rapid assay for Hendra virus IgG antibody detection and its titre estimation using magnetic nanoparticles and phycoerythrin | |
| Kokla et al. | Visualization of the membrane engineering concept: Evidence for the specific orientation of electroinserted antibodies and selective binding of target analytes | |
| RU2014125266A (ru) | Анализ содержания фибриногена | |
| JP2015508500A5 (pl) |